Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE)
India
· Delayed Price · Currency is INR 367.90
+13.40 (3.78%)
Jun 6, 2025, 3:29 PM IST
Dr. Agarwal's Health Care Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 17,110 | 13,322 | 10,180 | 6,961 | 4,712 |
| Revenue Growth (YoY) | 28.44% | 30.86% | 46.25% | 47.73% | - |
| Cost of Revenue | 9,622 | 7,663 | 5,859 | 4,025 | 1,839 |
| Gross Profit | 7,488 | 5,658 | 4,321 | 2,936 | 2,873 |
| Selling, General & Admin | - | 503.94 | 380.15 | 238.71 | 181.13 |
| Other Operating Expenses | 2,924 | 1,481 | 1,168 | 833.54 | 1,858 |
| Operating Expenses | 5,231 | 3,740 | 2,881 | 2,089 | 2,986 |
| Operating Income | 2,256 | 1,919 | 1,441 | 846.92 | -113.24 |
| Interest Expense | -1,088 | -956.21 | -719.73 | -453.99 | -415.26 |
| Interest & Investment Income | - | 80.25 | 48.48 | 32.34 | 11.97 |
| Earnings From Equity Investments | - | - | - | - | -7.01 |
| Currency Exchange Gain (Loss) | - | 24.67 | -20.05 | 81.92 | 9.64 |
| Other Non Operating Income (Expenses) | 450.2 | 41.87 | 28.3 | 15.57 | 4.89 |
| EBT Excluding Unusual Items | 1,619 | 1,110 | 777.55 | 522.76 | -509.01 |
| Impairment of Goodwill | -30.2 | - | - | - | - |
| Gain (Loss) on Sale of Investments | - | 246.69 | 46.62 | - | - |
| Gain (Loss) on Sale of Assets | - | 1.87 | 0.4 | -2.36 | -6.15 |
| Asset Writedown | - | - | - | - | -8.08 |
| Other Unusual Items | - | 47.62 | 11.34 | 47.23 | 32.73 |
| Pretax Income | 1,589 | 1,406 | 835.91 | 567.63 | -490.51 |
| Income Tax Expense | 495.1 | 455.17 | -196.39 | 135.99 | 100.3 |
| Earnings From Continuing Operations | 1,093 | 950.51 | 1,032 | 431.64 | -590.82 |
| Minority Interest in Earnings | -258.8 | -119.9 | -91.33 | -54.7 | 36.03 |
| Net Income | 834.6 | 830.61 | 940.97 | 376.94 | -554.78 |
| Net Income to Common | 834.6 | 830.61 | 940.97 | 376.94 | -554.78 |
| Net Income Growth | 0.48% | -11.73% | 149.63% | - | - |
| Shares Outstanding (Basic) | 298 | 265 | 235 | 206 | 206 |
| Shares Outstanding (Diluted) | 300 | 265 | 236 | 206 | 206 |
| Shares Change (YoY) | 13.23% | 12.46% | 14.56% | - | - |
| EPS (Basic) | 2.80 | 3.14 | 4.01 | 1.83 | -2.70 |
| EPS (Diluted) | 2.78 | 3.13 | 4.00 | 1.83 | -2.70 |
| EPS Growth | -11.18% | -21.75% | 118.58% | - | - |
| Free Cash Flow | 516.8 | 1,151 | 765.33 | 940.89 | -273.95 |
| Free Cash Flow Per Share | 1.72 | 4.34 | 3.25 | 4.57 | -1.33 |
| Gross Margin | 43.76% | 42.48% | 42.45% | 42.18% | 60.97% |
| Operating Margin | 13.19% | 14.41% | 14.15% | 12.17% | -2.40% |
| Profit Margin | 4.88% | 6.24% | 9.24% | 5.42% | -11.77% |
| Free Cash Flow Margin | 3.02% | 8.64% | 7.52% | 13.52% | -5.81% |
| EBITDA | 4,564 | 2,972 | 2,181 | 1,396 | 428.71 |
| EBITDA Margin | 26.67% | 22.31% | 21.42% | 20.06% | 9.10% |
| D&A For EBITDA | 2,307 | 1,053 | 740.28 | 549.42 | 541.94 |
| EBIT | 2,256 | 1,919 | 1,441 | 846.92 | -113.24 |
| EBIT Margin | 13.19% | 14.41% | 14.15% | 12.17% | -2.40% |
| Effective Tax Rate | 31.17% | 32.38% | - | 23.96% | - |
| Revenue as Reported | 17,570 | 13,764 | 10,315 | 7,138 | 4,771 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.